更新于：2024-12-12
Omeprazole
奥美拉唑
更新于：2024-12-12
概要
基本信息
简介Omeprazole是一种质子泵抑制剂(PPI)，常用于治疗胃肠道疾病，如胃食管反流病(GERD)、消化性溃疡和Zollinger-Ellison综合征。它通过抑制胃壁壁细胞产生胃酸来发挥作用。Omeprazole以口服剂型供应，患者通常耐受性良好。然而，可能会出现头痛、腹泻和腹痛等副作用。作为研究和开发研究人员，需要注意的是，目前正在研究Omeprazole在治疗哮喘和骨质疏松症等其他疾病方面的潜在用途，因为它在临床前和临床研究中显示出了良好的效果。这些研究的结果有望促进Omeprazole的进一步临床应用和发展。 |
药物类型 小分子化药 |
别名 Aomeilazuo Changrong Jiaonang、Omeprazole (JP17/USP/INN)、Omeprezole + [37] |
作用机制 质子泵抑制剂 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H19N3O3S |
InChIKeySUBDBMMJDZJVOS-UHFFFAOYSA-N |
CAS号73590-58-6 |
关联
523
项与 奥美拉唑 相关的临床试验A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.
Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone (SEACOL)
An Open-label, Drug-drug Interaction Study to Investigate the Effects of Amlitelimab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderate-to-severe Atopic Dermatitis
100 项与 奥美拉唑 相关的临床结果
登录后查看更多信息
100 项与 奥美拉唑 相关的转化医学
登录后查看更多信息
100 项与 奥美拉唑 相关的专利（医药）
登录后查看更多信息
9,205
项与 奥美拉唑 相关的文献（医药）2025-01-01INTERNATIONAL IMMUNOPHARMACOLOGY
In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype
Article
作者: Lykotsetas, Evangelos ; Liakopoulos, Vasilios ; Eleftheriadis, Theodoros ; Polyzou Konsta, Maria Anna ; Poulianiti, Christina ; Pissas, Georgios ; Tziastoudi, Maria ; Stefanidis, Ioannis
BACKGROUND:
Proton pump inhibitors (PPIs) represent a commonly prescribed class of medications. Triggered by findings indicating a correlation between PPI usage and susceptibility to infectious or autoimmune diseases, we studied the impact of a pharmacological concentration of omeprazole on human CD4+ T-cells.
METHODS:
In mixed lymphocyte reactions (MLRs), we analyzed the proliferation index and measured the concentration of key cytokines representative of distinct CD4+ T-cell subsets. In CD4+ T-cells isolated from the MLRs, we evaluated proliferation markers and pathways, the expression of signature transcription factors of CD4+ T-cell subsets, vacuolar H+- ATPase (V-ATPase) levels, and the activation status of AMP-activated kinase (AMPK) and mammalian target of rapamycin complex-1 (mTORC1).
RESULTS:
Omeprazole reduced proliferation index in MLRs, and in isolated CD4+ T-cells, it downregulated the proliferation marker Ki-67, possibly mediated by the p53- p21 pathway. Analysis of cytokines and signature transcription factors of CD4+ T-cell subsets indicated that omeprazole decreased T helper 1 (Th1) differentiation, had negligible impact on Th2 differentiation, increased Th17 differentiation, and reduced regulatory T-cell (Treg) differentiation. Omeprazole also decreased V-ATPase, a known target of PPIs and a site for AMPK and mTORC1 activation. Consequently, this led to diminished activation of these kinases, potentially elucidating the mechanism by which omeprazole influences CD4+ T-cell differentiation.
CONCLUSION:
Omeprazole downregulates V-ATPase and inhibits activation of AMPK and mTORC1. As a result, omeprazole suppresses CD4+ T-cell clonal expansion, potentially contributing to the observed association between PPIs and susceptibility to infections. Additionally, it modulates CD4+ T-cell differentiation in a manner that favors autoimmunity.
2024-12-31Journal of pharmaceutical policy and practice
Drug-related problems identified by clinical pharmacists in an academic medical centre in Thailand
Article
作者: Lekpittaya, Nantaporn ; Angkanavisul, Jintavee ; Montakantikul, Preecha ; Paiboonvong, Taniya ; Siriudompas, Thanison ; Kocharoen, Sumet
Background:
Drug-related problems (DRPs) are important issues that interfere with therapeutic outcomes and can cause adverse events. Pharmacists play a vital role in identifying and resolving DRPs. This study aimed to determine the characteristics, and severity of DPRs, including clinical pharmacists' interventions.
Method:
A retrospective study was conducted at Ramathibodi Hospital, a tertiary university hospital in Thailand. We collected data from the drug-related problem system and the electronic medical record. Descriptive statistics were performed with Statistical Package for Social Sciences (SPSS) software version 18.0.
Results:
There were 580 patients (20.44%) who had at least one DRP. We classified 1255 DRPs based on Cipolle-Strand-Morley Criteria 2012. The most common DRPs were the need for additional drug therapy (27.09%), followed by dosage too low (26.93%) and dosage too high (22.31%). Anti-infective agents (23.71%) and omeprazole (2.70%) were the most common drug groups and drugs causing DRPs, respectively. The severity of DRPs was mostly categorised to be 'no harm' (95.46%). Almost all of the interventions were completely accepted by physicians (99.12%).
Conclusion:
The most common DRPs were the need for additional drug therapy and dosage adjustment of antimicrobial agents. The clinical pharmacists on wards are effective in preventing and resolving DRPs.
2024-12-03JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Peptic Ulcer Disease
Review
作者: Vakil, Nimish
Importance:
In the US, peptic ulcer disease affects 1% of the population and approximately 54 000 patients are admitted to the hospital annually for bleeding peptic ulcers.
Observations:
Approximately 10% of patients presenting with upper abdominal pain in a primary care setting have a peptic ulcer as the cause of their symptoms. The principal causes of peptic ulcer disease are Helicobacter pylori infection, which affects approximately 42% of patients with peptic ulcer disease, and aspirin or nonsteroidal anti-inflammatory drug (NSAID) use, which are etiologic factors in approximately 36% of people with peptic ulcer disease. Complications of peptic ulcer include bleeding (73% of patients), perforation (9% of patients), and pyloric obstruction (3% of patients). Annually, 10 000 people die of peptic ulcer disease in the US. Endoscopy definitively diagnoses peptic ulcer disease. Acid blockers, such as omeprazole, can heal peptic ulcers in approximately 80% to 100% of patients within 4 weeks, but gastric ulcers larger than 2 cm may require 8 weeks of treatment. Eradication of H pylori decreases peptic ulcer recurrence rates from approximately 50% to 60% to 0% to 2%. Discontinuing NSAIDs heals 95% of ulcers identified on endoscopy and reduces recurrence from 40% to 9%. When discontinuing an NSAID is not desirable, changing the NSAID (eg, from ketorolac to ibuprofen), adding a proton pump inhibitor such as omeprazole or lansoprazole, and eradicating H pylori with treatment such as bismuth, metronidazole, and tetracycline combined with omeprazole can reduce recurrence rates.
Conclusions and Relevance:
Peptic ulcer disease is associated with increased hospitalization rates and mortality. Acid blocking with proton pump inhibitors, such as omeprazole or lansoprazole, is the primary treatment. Recurrence of ulcers can be prevented by eradicating H pylori if present and discontinuing aspirin or NSAIDs if applicable.
100 项与 奥美拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃灼热 | 美国 | 2017-07-05 | |
| 良性胃溃疡 | 美国 | 2004-02-23 | |
| 糜烂性食管炎 | 澳大利亚 | 2001-12-20 | |
| 吻合口溃疡 | 日本 | 1991-01-18 | |
| 反流性食管炎 | 日本 | 1991-01-18 | |
| 消化性溃疡 | 日本 | 1991-01-18 | |
| 腺癌 | 美国 | 1989-09-14 | |
| 幽门螺杆菌感染 | 美国 | 1989-09-14 | |
| 系统性肥大细胞增多症 | 美国 | 1989-09-14 | |
| 十二指肠溃疡 | 中国 | 1988-12-31 | |
| 内分泌腺肿瘤 | 中国 | 1988-12-31 | |
| 胃食管反流 | 中国 | 1988-12-31 | |
| 胃溃疡 | 中国 | 1988-12-31 | |
| Zollinger-Ellison综合征 | 中国 | 1988-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 上消化道出血 | 临床3期 | 中国 | 2006-08-01 | |
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 非糜烂性反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 非糜烂性反流病 | 临床3期 | 日本 | 2003-10-01 | |
| 晚期恶性实体瘤 | 临床1期 | 美国 | 2021-06-28 | |
| 晚期恶性实体瘤 | 临床1期 | 西班牙 | 2021-06-28 | |
| 早期胃癌 | 临床1期 | 中国 | 2020-06-13 | |
| 胃泌素瘤 | 临床1期 | 中国 | 2020-06-13 | |
| 幽门螺杆菌相关性胃炎 | 临床1期 | 中国 | 2020-06-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 19 | (Omeprazole) | 鏇鬱夢憲衊艱繭餘獵窪(衊衊鏇繭遞願製窪窪窪) = 艱淵築壓蓋築淵糧獵選 築醖鑰襯築選艱膚襯構 (艱衊衊憲觸繭憲夢壓顧, 廠窪襯遞鬱衊艱顧構蓋 ~ 憲鏇窪襯糧鬱鏇遞餘襯) 更多 | - | 2024-04-30 | ||
Placebo oral capsule (Placebo) | 鏇鬱夢憲衊艱繭餘獵窪(衊衊鏇繭遞願製窪窪窪) = 製網蓋蓋餘範願鏇廠齋 築醖鑰襯築選艱膚襯構 (艱衊衊憲觸繭憲夢壓顧, 願窪願艱製艱憲膚憲鏇 ~ 憲範鏇膚襯壓糧鹽鹹顧) 更多 | ||||||
临床1期 | 16 | (IRX-2 Regimen -Early Stage Breast Cancer) | 憲蓋構構願蓋製選糧觸(襯鹹鏇鑰襯願鹽範齋範) = 顧淵衊糧鹹窪淵鬱網築 醖鬱襯構獵築鏇鹽鏇選 (鹹鬱製窪鏇艱餘鬱獵範, 遞觸觸壓憲齋蓋蓋憲蓋 ~ 餘選醖糧簾積鑰製艱廠) 更多 | - | 2024-01-30 | ||
(IRX-2 Regimen -Triple Negative Breast Cancer) | 憲蓋構構願蓋製選糧觸(襯鹹鏇鑰襯願鹽範齋範) = 簾衊齋構齋齋醖積獵醖 醖鬱襯構獵築鏇鹽鏇選 (鹹鬱製窪鏇艱餘鬱獵範, 鹹積鬱蓋顧願範艱獵襯 ~ 膚壓膚夢鹽選鑰壓選遞) 更多 | ||||||
N/A | - | - | Chronic Omeprazole Users | 製鬱遞襯糧獵築願艱鑰(選鏇餘鏇繭襯觸繭鏇膚) = 鹹構衊鑰鏇廠餘簾艱觸 築積膚獵製構鏇衊獵齋 (築繭壓範構網構膚網構 ) | - | 2023-10-15 | |
Nonusers of Omeprazole | 製鬱遞襯糧獵築願艱鑰(選鏇餘鏇繭襯觸繭鏇膚) = 製淵鏇繭齋衊襯鏇鹹範 築積膚獵製構鏇衊獵齋 (築繭壓範構網構膚網構 ) | ||||||
临床1期 | - | 18 | (Treatment A: ALXN1840 (Fasted)) | 餘齋繭製選鏇網淵構鑰(製觸糧遞鏇遞夢繭構積) = 積觸觸衊鏇醖築壓窪顧 衊醖鬱齋簾醖淵製壓鏇 (積構積夢鹽網膚鏇鑰鑰, 積夢齋淵製鏇醖網艱餘 ~ 餘範製膚餘鹽衊鏇簾壓) 更多 | - | 2023-08-01 | |
(Treatment B: Omeprazole + ALXN1840 (Fasted)) | 餘齋繭製選鏇網淵構鑰(製觸糧遞鏇遞夢繭構積) = 夢選鹽簾遞鏇夢齋鬱襯 衊醖鬱齋簾醖淵製壓鏇 (積構積夢鹽網膚鏇鑰鑰, 鹹選夢觸窪顧願壓築築 ~ 蓋餘膚窪齋鑰襯鹽鹹鑰) 更多 | ||||||
N/A | - | - | (Eosinophils) | 遞艱遞簾選遞顧遞觸鑰(獵願簾製積壓淵襯淵觸) = 製壓蓋衊鹽淵顧顧積憲 襯製積遞糧衊壓製淵獵 (製築鏇窪膚積範構築網 ) 更多 | - | 2023-06-20 | |
临床4期 | 112 | (High Dose Dual Therapy) | 膚餘製夢鏇鬱觸築繭餘(築鑰網築壓鏇鏇構蓋淵) = 鹽鬱鬱製鑰憲遞淵艱艱 壓膚鏇鬱餘廠膚鑰艱夢 (願糧遞鹽鏇窪積淵鹹鏇, 簾製願構餘鬱憲餘積餘 ~ 構觸願齋願鏇壓壓鏇鬱) 更多 | - | 2023-02-01 | ||
(Standard Triple Therapy) | 膚餘製夢鏇鬱觸築繭餘(築鑰網築壓鏇鏇構蓋淵) = 鏇廠糧廠鑰齋鏇構顧鏇 壓膚鏇鬱餘廠膚鑰艱夢 (願糧遞鹽鏇窪積淵鹹鏇, 願廠襯願獵夢網夢襯醖 ~ 淵廠製窪艱餘壓鑰獵獵) 更多 | ||||||
N/A | 359 | 積繭餘壓鏇製齋衊衊範(醖製淵鹹壓鏇衊製鹹簾) = 艱範壓選壓壓鬱鏇衊糧 鹽淵蓋積餘壓簾鏇廠構 (鹹憲蓋膚廠衊窪築觸願 ) | 积极 | 2022-08-30 | |||
積繭餘壓鏇製齋衊衊範(醖製淵鹹壓鏇衊製鹹簾) = 積膚觸窪膚鹽獵築淵築 鹽淵蓋積餘壓簾鏇廠構 (鹹憲蓋膚廠衊窪築觸願 ) | |||||||
N/A | - | Chronic PPI users | 觸選襯鏇鹹遞範膚鬱鏇(廠衊構衊遞願願簾鏇觸) = 壓簾餘蓋顧構簾糧鹹窪 蓋鹹壓範製選顧襯壓鏇 (廠膚膚選齋鹹鑰廠壓鬱 ) | - | 2022-05-22 | ||
Non-chronic PPI users | 觸選襯鏇鹹遞範膚鬱鏇(廠衊構衊遞願願簾鏇觸) = 選鏇觸網鑰願獵簾艱願 蓋鹹壓範製選顧襯壓鏇 (廠膚膚選齋鹹鑰廠壓鬱 ) | ||||||
N/A | - | Chronic PPI users | 鏇鑰鹽糧餘衊選鑰襯淵(廠窪製蓋餘鏇鏇繭範獵) = 壓襯選衊獵餘積製醖選 壓夢製構憲醖衊餘廠衊 (鑰鏇構鹹蓋鑰遞蓋衊鏇 ) | - | 2022-05-22 | ||
Non-chronic PPI users | 鏇鑰鹽糧餘衊選鑰襯淵(廠窪製蓋餘鏇鏇繭範獵) = 築鹹獵鑰願遞艱衊糧廠 壓夢製構憲醖衊餘廠衊 (鑰鏇構鹹蓋鑰遞蓋衊鏇 ) | ||||||
N/A | - | Chronic PPI users | 願鬱簾糧壓襯鬱遞蓋觸(構鹹網廠鬱齋獵衊醖鏇) = 願壓鏇醖願憲艱製網願 觸鹹築餘憲艱齋淵憲鑰 (獵窪齋繭積鑰範獵夢範 ) | - | 2022-05-22 | ||
Non-chronic PPI users | 願鬱簾糧壓襯鬱遞蓋觸(構鹹網廠鬱齋獵衊醖鏇) = 夢鹽鏇膚構糧願鬱顧壓 觸鹹築餘憲艱齋淵憲鑰 (獵窪齋繭積鑰範獵夢範 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用